Exclusive Commercialization Partnership With Clinigen for Xervyteg® in aGvHD

Exclusive Commercialization Partnership
With Clinigen for Xervyteg® in aGvHD

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

October 7, 2025

October 7, 2025: MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

September 23, 2025

September 22, 2025: Interview of Eric Soyer, CFO at MaaT Pharma – Boursier.com (French Only)

September 17, 2025

September 17, 2025: MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update

Like what you see? See more posts

Our upcoming events

Event
October 6, 2025

Portzamparc’s digital Biotech & Health Seminar 2025

Portzamparc’s digital Biotech & Health Seminar 2025 - October 1, 2025
MaaT Pharma
Event
October 6, 2025

Entretiens Jacques Cartier 2025 – Symposium

Entretiens Jacques Cartier 2025 | Symposium - October 8, 2025
MaaT Pharma
Event
October 6, 2025

Musée de sciences biologiques Dr Mérieux – Conference

Musée de sciences biologiques Dr Mérieux Annual Conference - October 9, 2025
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers